Literature DB >> 24361783

Interactions of atenolol with alprazolam/escitalopram on anxiety, depression and oxidative stress.

Naiyer Shahzad1, Javed Ahmad2, Wajahatullah Khan3, Saeed S Al-Ghamdi4, M Ruhal Ain5, Ibrahim Abdel Aziz Ibrahim4, Mohd Akhtar5, Razia Khanam6.   

Abstract

Anxiety and depression are highly comorbid disorders possibly sharing a common neurobiological mechanism. The dysfunction of serotoninergic, noradrenergic and dopaminergic neurotransmission, abnormal regulation in the hypothalamic-pituitary-adrenal axis (HPA), disturbance of cellular plasticity including reduced neurogenesis, or chronic inflammation connected with high oxidative damage play a crucial role in the development of anxiety and depression. The present study was aimed to investigate the effects of atenolol alone and in combination with alprazolam/escitalopram on anxiety, depression and oxidative stress. Wistar albino rats were subjected to 21 day treatment of drugs then exposed to elevated-plus maze (EPM) and modified forced swim test (MFST), and oxidative stress markers were estimated in isolated brain tissue of all groups. The results indicated that atenolol in combination with alprazolam/escitalopram exhibited antidepressant effects by significantly decreasing the immobility and increasing the swimming behavior in the MFST and anti-anxiety effects by increasing the percentage preference and number of open arm entries as well as time spent in open arm in EPM. Pretreatment with atenolol alone and combination with alprazolam/escitalopram also ameliorated tissue glutathione (GSH) and decreased malondialdehyde (MDA) level significantly which explore antioxidant properties of drugs, and combination augments the therapeutic response of monotherapy in depression. In conclusion behavioral and biological findings indicate that the combination of atenolol with alprazolam/escitalopram has the potential of being highly efficacious in treating anxiety and depressive disorders as well as oxidative stress.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Depression; Elevated-plus maze; Malondialdehyde; Modified forced swim test; Oxidative stress

Mesh:

Substances:

Year:  2013        PMID: 24361783     DOI: 10.1016/j.pbb.2013.12.015

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

1.  Acute and chronic treatment with quetiapine induces antidepressant-like behavior and exerts antioxidant effects in the rat brain.

Authors:  Zuleide M Ignácio; Gislaine Z Réus; Helena M Abelaira; Airam B de Moura; Thays G de Souza; Danyela Matos; Mariana P Goldim; Khiany Mathias; Leandro Garbossa; Fabricia Petronilho; João Quevedo
Journal:  Metab Brain Dis       Date:  2017-05-06       Impact factor: 3.584

2.  β1-adrenergic receptors mediate plasma acyl-ghrelin elevation and depressive-like behavior induced by chronic psychosocial stress.

Authors:  Deepali Gupta; Jen-Chieh Chuang; Bharath K Mani; Kripa Shankar; Juan A Rodriguez; Sherri Osborne-Lawrence; Nathan P Metzger; Jeffrey M Zigman
Journal:  Neuropsychopharmacology       Date:  2019-02-08       Impact factor: 7.853

3.  Surface-functionalized curcumin-loaded polymeric nanocapsules could block apomorphine-induced behavioral changes in rats.

Authors:  Camila de Oliveira Pacheco; Marcelo Gomes de Gomes; Manoel Rodrigues da Silva Neto; Alcides José Martins Parisotto; Renata Bem Dos Santos; Tamara Ramos Maciel; Ana Cláudia Funguetto Ribeiro; Renata Giacomeli; Sandra Elisa Haas
Journal:  Pharmacol Rep       Date:  2021-11-05       Impact factor: 3.024

4.  LOWER POSTERIOR CINGULATE CORTEX GLUTATHIONE LEVELS IN OBSESSIVE-COMPULSIVE DISORDER.

Authors:  Brian P Brennan; J Eric Jensen; Christine Perriello; Harrison G Pope; Michael A Jenike; James I Hudson; Scott L Rauch; Marc J Kaufman
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-02-01

5.  Curcumin Alters Neural Plasticity and Viability of Intact Hippocampal Circuits and Attenuates Behavioral Despair and COX-2 Expression in Chronically Stressed Rats.

Authors:  Ga-Young Choi; Hyun-Bum Kim; Eun-Sang Hwang; Seok Lee; Min-Ji Kim; Ji-Young Choi; Sung-Ok Lee; Sang-Seong Kim; Ji-Ho Park
Journal:  Mediators Inflamm       Date:  2017-01-11       Impact factor: 4.711

6.  Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder.

Authors:  Yongjie Zhou; Zhongqiang Cao; Mei Yang; Xiaoyan Xi; Yiyang Guo; Maosheng Fang; Lijuan Cheng; Yukai Du
Journal:  Sci Rep       Date:  2017-01-18       Impact factor: 4.379

7.  Effect of Fluoxetine Administration on Clinical and Echocardiographic Findings in Patients with Mitral Valve Prolapse and Generalized Anxiety Disorder: Randomized Clinical Trial.

Authors:  Reza Jafarzadeh Esfehani; Homan Kamranian; Majid Jalalyazdi
Journal:  Electron Physician       Date:  2017-01-25

8.  Preliminary evidence of acylated ghrelin association with depression severity in postmenopausal women.

Authors:  Maria Fernanda Naufel; Amanda Paula Pedroso; Lila Missae Oyama; Mônica Marques Telles; Helena Hachul; Eliane Beraldi Ribeiro
Journal:  Sci Rep       Date:  2021-03-05       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.